Amplia Therapeutics has used one of the world’s largest oncology stages to sharpen its case for narmafotinib, presenting mature data from its ACCENT trial that suggest the drug could meaningfully shift outcomes in one of the most difficult-to-treat cancers. …
Amplia positions narmafotinib as a potential step change in pancreatic cancer
April 22, 2026 Australian Biotech
Latest Video
New Stories
-
Pharmac announces plan to revise its recently expanded patient advisory function
August 4, 2026 - - Latest News -
Australian company announces agreement with Lilly to trial lung cancer combination
August 4, 2026 - - Latest News -
The complete absence of patient power and agency makes this a health system outlier
August 4, 2026 - - Latest News -
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News